13F Pro quality score
Rank #2,787 of 2,925
Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.
Net Income
Q4 202613fpro.ai/company/INM
13fpro.ai/company/INM
Reported revenue, net income and operating margin by fiscal year, from InMed Pharmaceuticals Inc.'s annual filings on SEC EDGAR.
| Period | Form | Revenue | Net income | Op. marginOperating margin |
|---|---|---|---|---|
| FY 2025 | 10-K | $4.9M | $-8.2M | -175.8% |
| FY 2024 | 10-K | $4.6M | $-7.7M | -166.8% |
| FY 2023 | 10-K | $4.1M | $-7.9M | -192.2% |
| FY 2022 | 10-K | $1.1M | $-18.6M | — |
| FY 2021 | 10-K | $1.9M | $-10.2M | — |
Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.
InMed Pharmaceuticals Inc. (INM) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INM at 17.5/100 on a composite quality score built from its SEC filings, placing it at rank #2,787 of 2,925 stocks — the bottom half of the AI-ranked universe. Top institutional holders of INM by reported 13-F value include ADAR1 Capital Management, Vivo Capital, Squadron Capital Management, based on the most recent SEC filings. INM trades on the Nasdaq exchange and files with the SEC under CIK 1728328. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for InMed Pharmaceuticals Inc. directly from SEC EDGAR.
Financials through the period ended SEC EDGAR: CIK 1728328 →